Stock Ratings / Health Care / IMDX / dividends

ICCC (50) TKNO (44) NNNN (45) MYGN (39) ⌘ Pro Terminal →

Insight Molecular Diagnostics Inc. (IMDX) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.18 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.17

Insight Molecular Diagnostics Inc. (IMDX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $104.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.17 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMDX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY IMDX SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (35% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.37-10.7% Next Q

Q2 (-2Q)

Grade E$3.01-6% Next Q

Q3 (-1Q)

Grade E$2.83+12.4% Next Q

Current

Grade E$3.18-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMDX currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.62) and Max Pain ($3.34) forces dealer call-delta covering toward $8.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IMDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMDX)

✓Walkthrough of IMDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.70%⚡ TESTING RESISTANCE

2026-10-30O $3.12H $3.18L $2.95C $3.18VOL 62.0K

RES: $3.39SUP: $2.35SMA50: $3.62SMA200: $4.73

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMDX Butterfly Map → + Track IMDX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +115.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMDX)

Health Care Rank #927 of 1016 ⚔️ ICCC vs IMDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMDX vs. ICCC, TKNO, NNNN, MYGN)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Insight Molecular Diagnostics Inc. (IMDX) ranks #927 by composite RQD confidence (31/100, grade E) and #657 by equity capitalization ($104.1M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. ICCC currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with IMDX at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMDX ACTIVE Insight Molecular Diagnostics Inc.	E	31/100	—	56.7%	-35.0%	0.00%	$104.1M	Benchmark Subject
ICCC ImmuCell Corporation	D	50/100	—	41.4%	4.2%	-2.82%	$93.7M	/iccc-vs-imdx →
TKNO Alpha Teknova Inc.	D	44/100	—	33.2%	-21.3%	+2.93%	$499.2M	/tkno-vs-imdx →
NNNN Anbio Biotechnology (Class A)	D	45/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	/nnnn-vs-imdx →
MYGN Myriad Genetics Inc.	D-	39/100	—	69.9%	-35.0%	+0.60%	$638.0M	/mygn-vs-imdx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001642380

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insight Molecular Diagnostics Inc. (IMDX) reported GAAP revenue of $4.1M (+115.6% vs. FY2024 revenue of $1.9M , and +169.8% cumulative change since FY2023) , GAAP net income of -$50.2K, operating cash flow of -$22.2M, and free cash flow of -$25.4M (-19.6% YoY). On the balance sheet, IMDX closed FY2025 with $25.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.1M	-$50.2K	-$22.2M	-$25.4M	$25.8M	—
FY2024 (FY)	2024-12-31	$1.9M	-$60.7K	-$20.7M	-$21.2M	$35.1M	—
FY2023 (FY)	2023-12-31	$1.5M	-$27.8K	-$23.3M	-$23.3M	—	—

3. IMDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.18 (0.00% 1D, market cap $104.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMDX ranks #927 in composite RQD confidence.

How does IMDX compare to ICCC and TKNO in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), IMDX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 56.7%, and ROIC of -35.0%. By comparison, ICCC (ImmuCell Corporation) holds a D grade (50/100 RQD, P/E N/A, ROIC 4.2%, cap $93.7M) and TKNO (Alpha Teknova Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.3%, cap $499.2M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMDX?

Per IMDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001642380), Insight Molecular Diagnostics Inc. generated $4.1M in revenue (+115.6% YoY), -$50.2K in net income, and -$25.4M in free cash flow against $25.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMDX trading relative to its 50-day, 200-day, and 52-week technical levels?

IMDX last traded at $3.18 (0.00% on volume of 111,912 shares), positioning the stock -12.15% below its 50-day simple moving average ($3.62) and -32.77% below its 200-day simple moving average ($4.73). Across its 52-week range of $2.42 to $8.51, IMDX sits at the 12.5% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.78 to $3.58).

IMDX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does IMDX pay a dividend and is it safe?

Insight Molecular Diagnostics Inc. (IMDX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: IMDX RQD Cockpit IMDX 12M Forecast IMDX Earnings & Move IMDX Dividends & DRIP IMDX Insiders & 13F IMDX Whale Options IMDX Profit Sankey IMDX News & Why